Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 21

1.

Cell type-selective pathways and clinical associations of lysophosphatidic acid biosynthesis and signaling in the ovarian cancer microenvironment.

Reinartz S, Lieber S, Pesek J, Brandt DT, Asafova A, Finkernagel F, Watzer B, Nockher WA, Nist A, Stiewe T, Jansen JM, Wagner U, Konzer A, Graumann J, Grosse R, Worzfeld T, Müller-Brüsselbach S, Müller R.

Mol Oncol. 2019 Feb;13(2):185-201. doi: 10.1002/1878-0261.12396. Epub 2018 Nov 15.

2.

The Combination of MiRNA-196b, LCN2, and TIMP1 is a Potential Set of Circulating Biomarkers for Screening Individuals at Risk for Familial Pancreatic Cancer.

Bartsch DK, Gercke N, Strauch K, Wieboldt R, Matthäi E, Wagner V, Rospleszcz S, Schäfer A, Franke FS, Mintziras I, Bauer C, Grote T, Figiel J, Di Fazio P, Burchert A, Reinartz S, Pogge von Strandmann E, Klöppel G, Slater EP.

J Clin Med. 2018 Sep 20;7(10). pii: E295. doi: 10.3390/jcm7100295.

3.

Chromatin Binding of c-REL and p65 Is Not Limiting for Macrophage IL12B Transcription During Immediate Suppression by Ovarian Carcinoma Ascites.

Unger A, Finkernagel F, Hoffmann N, Neuhaus F, Joos B, Nist A, Stiewe T, Visekruna A, Wagner U, Reinartz S, Müller-Brüsselbach S, Müller R, Adhikary T.

Front Immunol. 2018 Jun 27;9:1425. doi: 10.3389/fimmu.2018.01425. eCollection 2018.

4.

Prognosis of ovarian cancer is associated with effector memory CD8+ T cell accumulation in ascites, CXCL9 levels and activation-triggered signal transduction in T cells.

Lieber S, Reinartz S, Raifer H, Finkernagel F, Dreyer T, Bronger H, Jansen JM, Wagner U, Worzfeld T, Müller R, Huber M.

Oncoimmunology. 2018 Mar 15;7(5):e1424672. doi: 10.1080/2162402X.2018.1424672. eCollection 2018.

5.

Proteotranscriptomics Reveal Signaling Networks in the Ovarian Cancer Microenvironment.

Worzfeld T, Finkernagel F, Reinartz S, Konzer A, Adhikary T, Nist A, Stiewe T, Wagner U, Looso M, Graumann J, Müller R.

Mol Cell Proteomics. 2018 Feb;17(2):270-289. doi: 10.1074/mcp.RA117.000400. Epub 2017 Nov 15.

6.

Soluble NKG2D ligands in the ovarian cancer microenvironment are associated with an adverse clinical outcome and decreased memory effector T cells independent of NKG2D downregulation.

Vyas M, Reinartz S, Hoffmann N, Reiners KS, Lieber S, Jansen JM, Wagner U, Müller R, von Strandmann EP.

Oncoimmunology. 2017 Aug 21;6(9):e1339854. doi: 10.1080/2162402X.2017.1339854. eCollection 2017.

7.

Tumor-Host Cell Interactions in Ovarian Cancer: Pathways to Therapy Failure.

Pogge von Strandmann E, Reinartz S, Wager U, Müller R.

Trends Cancer. 2017 Feb;3(2):137-148. doi: 10.1016/j.trecan.2016.12.005. Epub 2017 Jan 18. Review.

8.

Interferon signaling in ascites-associated macrophages is linked to a favorable clinical outcome in a subgroup of ovarian carcinoma patients.

Adhikary T, Wortmann A, Finkernagel F, Lieber S, Nist A, Stiewe T, Wagner U, Müller-Brüsselbach S, Reinartz S, Müller R.

BMC Genomics. 2017 Mar 21;18(1):243. doi: 10.1186/s12864-017-3630-9.

9.

The Unique Molecular and Cellular Microenvironment of Ovarian Cancer.

Worzfeld T, Pogge von Strandmann E, Huber M, Adhikary T, Wagner U, Reinartz S, Müller R.

Front Oncol. 2017 Feb 22;7:24. doi: 10.3389/fonc.2017.00024. eCollection 2017. Review.

10.

The transcriptional signature of human ovarian carcinoma macrophages is associated with extracellular matrix reorganization.

Finkernagel F, Reinartz S, Lieber S, Adhikary T, Wortmann A, Hoffmann N, Bieringer T, Nist A, Stiewe T, Jansen JM, Wagner U, Müller-Brüsselbach S, Müller R.

Oncotarget. 2016 Nov 15;7(46):75339-75352. doi: 10.18632/oncotarget.12180.

11.

A transcriptome-based global map of signaling pathways in the ovarian cancer microenvironment associated with clinical outcome.

Reinartz S, Finkernagel F, Adhikary T, Rohnalter V, Schumann T, Schober Y, Nockher WA, Nist A, Stiewe T, Jansen JM, Wagner U, Müller-Brüsselbach S, Müller R.

Genome Biol. 2016 May 23;17(1):108. doi: 10.1186/s13059-016-0956-6.

12.

Deregulation of PPARβ/δ target genes in tumor-associated macrophages by fatty acid ligands in the ovarian cancer microenvironment.

Schumann T, Adhikary T, Wortmann A, Finkernagel F, Lieber S, Schnitzer E, Legrand N, Schober Y, Nockher WA, Toth PM, Diederich WE, Nist A, Stiewe T, Wagner U, Reinartz S, Müller-Brüsselbach S, Müller R.

Oncotarget. 2015 May 30;6(15):13416-33.

13.

The transcriptional PPARβ/δ network in human macrophages defines a unique agonist-induced activation state.

Adhikary T, Wortmann A, Schumann T, Finkernagel F, Lieber S, Roth K, Toth PM, Diederich WE, Nist A, Stiewe T, Kleinesudeik L, Reinartz S, Müller-Brüsselbach S, Müller R.

Nucleic Acids Res. 2015 May 26;43(10):5033-51. doi: 10.1093/nar/gkv331. Epub 2015 Apr 30.

14.

Mixed-polarization phenotype of ascites-associated macrophages in human ovarian carcinoma: correlation of CD163 expression, cytokine levels and early relapse.

Reinartz S, Schumann T, Finkernagel F, Wortmann A, Jansen JM, Meissner W, Krause M, Schwörer AM, Wagner U, Müller-Brüsselbach S, Müller R.

Int J Cancer. 2014 Jan 1;134(1):32-42. doi: 10.1002/ijc.28335. Epub 2013 Jul 19.

15.

CA125 (MUC16) gene silencing suppresses growth properties of ovarian and breast cancer cells.

Reinartz S, Failer S, Schuell T, Wagner U.

Eur J Cancer. 2012 Jul;48(10):1558-69. doi: 10.1016/j.ejca.2011.07.004. Epub 2011 Aug 16.

PMID:
21852110
16.

Suppressive activity rather than frequency of FoxP3(+) regulatory T cells is essential for CA-125-specific T-cell activation after abagovomab treatment.

Reinartz S, Pfisterer J, du Bois A, Jackisch C, Baumann KH, Wagner U.

Hum Immunol. 2010 Jan;71(1):36-44. doi: 10.1016/j.humimm.2009.09.356.

PMID:
19782714
17.

Effects of celecoxib and ly117018 combination on human breast cancer cells in vitro.

Baumann KH, Klusmeier E, Eggemann I, Reinartz S, Almeroth A, Kalder M, Wagner U.

Breast Cancer (Auckl). 2009 Apr 7;3:23-34.

18.

Phase I study of abagovomab in patients with epithelial ovarian, fallopian tube, or primary peritoneal cancer.

Sabbatini P, Dupont J, Aghajanian C, Derosa F, Poynor E, Anderson S, Hensley M, Livingston P, Iasonos A, Spriggs D, McGuire W, Reinartz S, Schneider S, Grande C, Lele S, Rodabaugh K, Kepner J, Ferrone S, Odunsi K.

Clin Cancer Res. 2006 Sep 15;12(18):5503-10.

19.

Development of a delivery system for the continuous endogenous release of an anti-idiotypic antibody against ovarian carcinoma.

Hann E, Reinartz S, Clare SE, Passow S, Kissel T, Wagner U.

Hybridoma (Larchmt). 2005 Jun;24(3):133-40.

PMID:
15943560
20.

Vaccination of patients with advanced ovarian carcinoma with the anti-idiotype ACA125: immunological response and survival (phase Ib/II).

Reinartz S, Köhler S, Schlebusch H, Krista K, Giffels P, Renke K, Huober J, Möbus V, Kreienberg R, DuBois A, Sabbatini P, Wagner U.

Clin Cancer Res. 2004 Mar 1;10(5):1580-7.

Supplemental Content

Loading ...
Support Center